Piper Sandler analyst Allison Bratzel raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $23 from $15 driven by pipeline developments. The firm keeps a Neutral rating on the shares following quarterly results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL: